Glenmark Pharmaceuticals Ltd has announced that its leading compound GRC 8200 for the treatment of Type II Diabetes has received the international non-proprietary name (INN) "Melogliptin", from the World Health Organisation (WHO).

The name was selected during the recently held 45th Consultation on non-proprietary names and was suggested by the International Panel for Pharmacopoeia and Pharmaceutical Preparations.

GRC 8200 from Glenmark, is a novel and oral DPPIV inhibitor for type 2 diabetes. It is currently in Phase II clinical trials. Phase I studies showed that the compound was very well tolerated by the subjects at all dosage levels and there were no significant adverse events reported.

Glenmark Pharmaceuticals Ltd. is a research-driven, global, fully integrated pharmaceutical company headquartered at Mumbai, India. The Company is a leader in India in the discovery of new molecules and is focused in the areas of inflammation [Asthma/COPD, etc] and metabolic disorders [Diabetes, Obesity, etc].The Company has generic formulation and API business interests in over 85 countries across the world including the regulated markets of USA and Europe.

The stock closed today at Rs. 577 on NSE, up by 7% compared with previous close of Rs. 542. It touched an intraday high of Rs. 582 and low of Rs. 545.